Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies
暂无分享,去创建一个
Marina Sirota | Shobha Potluri | Arvind Rajpal | M. Sirota | S. Potluri | J. Chaparro-Riggers | A. Rajpal | J. Pons | W. Zhai | D. McDonough | S. Pitts | P. Sundar | Andrea Rossi | Meritxell Galindo Casas | Andrea Rossi | Javier Chaparro-Riggers | Jaume Pons | Thomas Van Blarcom | Purnima Sundar | Steven Pitts | Zea Melton | Wai Ling Cheung | Wenwu Zhai | Kevin Lindquist | Zygy Roe-Zurz | Chris Wagstrom | Dan McDonough | Cendy Valle Oseguera | Sheng Ding | Meri Galindo Casas | Yu Yan | Jeffrey Jones | Surabhi Srivatsa Srinivasan | Sheng Ding | Kevin C. Lindquist | Thomas J. Van Blarcom | Z. Roe-Žurž | W. Cheung | Z. Melton | C. Wagstrom | Cendy A. Valle Oseguera | Yu Yan | Jeffrey Jones | Surabhi Srivatsa Srinivasan | Christopher R. Wagstrom
[1] W. Es. VH shuffling can be used to convert an Fv fragment of anti-hen egg lysozyme specificity to one that recognizes a T cell receptor Vα , 1995 .
[2] Meric A. Ovacik,et al. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells , 2016, mAbs.
[3] J. Xu,et al. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. , 2000, Immunity.
[4] Andrew Leaver-Fay,et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface , 2014, Nature Biotechnology.
[5] Ulrik B. Nielsen,et al. Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.
[6] Christilyn P. Graff,et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity , 2011, mAbs.
[7] Irving L. Weissman,et al. Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands , 2015, Cell.
[8] Tsukasa Suzuki,et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.
[9] D. Cox,et al. Synthetic antibodies designed on natural sequence landscapes. , 2011, Journal of molecular biology.
[10] K Dane Wittrup,et al. Biophysical properties of the clinical-stage antibody landscape , 2017, Proceedings of the National Academy of Sciences.
[11] Michael J. Gramer,et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange , 2013, Proceedings of the National Academy of Sciences.
[12] D. Röthlisberger,et al. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. , 2005, Journal of molecular biology.
[13] A. Nesbitt,et al. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[14] Yvonne Stark,et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties , 2013, mAbs.
[15] A. Nisonoff,et al. Recombination of a mixture of univalent antibody fragments of different specificity. , 1961, Archives of biochemistry and biophysics.
[16] S. Urlinger,et al. In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology. , 2009, Immunotherapy.
[17] A. Lesk,et al. Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.
[18] David G Myszka,et al. Screening antibody-antigen interactions in parallel using Biacore A100. , 2006, Analytical biochemistry.
[19] P. Kufer,et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab , 2009, Leukemia & lymphoma.
[20] S. Sidhu,et al. Synthetic antibodies: concepts, potential and practical considerations. , 2012, Methods.
[21] P. Hudson,et al. Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.
[22] P. Parren,et al. Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models , 2017, Scientific Reports.
[23] K Dane Wittrup,et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. , 2013, Protein engineering, design & selection : PEDS.
[24] G. Raghunathan,et al. Antigen‐binding site anatomy and somatic mutations in antibodies that recognize different types of antigens , 2012, Journal of molecular recognition : JMR.
[25] M. Cragg,et al. Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies , 2015, Cancer cell.
[26] K. Walker,et al. Automated high-throughput protein purification using an ÄKTApurifier and a CETAC autosampler. , 2014, Journal of chromatography. A.
[27] Andreas Plückthun,et al. Biophysical properties of human antibody variable domains. , 2003, Journal of molecular biology.
[28] W. Luk,et al. Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.
[29] G. Mufti,et al. Role of 4-1BB:4-1BB ligand in cancer immunotherapy , 2004, Cancer Gene Therapy.
[30] George Georgiou,et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire , 2014, Nature Medicine.
[31] Lieping Chen,et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.
[32] Jan Beck,et al. Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display , 2017, Protein engineering, design & selection : PEDS.
[33] R. Karlsson,et al. Detection of antigen—antibody interactions by surface plasmon resonance. Application to Epitope Mapping , 1990, Journal of molecular recognition : JMR.
[34] S. Sidhu,et al. Bivalent antibody phage display mimics natural immunoglobulin. , 2004, Journal of immunological methods.
[35] Camellia W. Adams,et al. An efficient route to human bispecific IgG , 1998, Nature Biotechnology.
[36] Sampath R. Kumar,et al. Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients , 2017, mAbs.
[37] A. Plückthun,et al. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. , 2013, Structure.
[38] Adam R Miles,et al. Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms , 2015, mAbs.
[39] Yves Poitevin,et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG , 2015, Nature Communications.
[40] L. Presta,et al. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.
[41] Frederic A. Fellouse,et al. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. , 2004, Journal of molecular biology.
[42] Ulrich Brinkmann,et al. The making of bispecific antibodies , 2017, mAbs.
[43] Diego Ellerman,et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.
[44] Thomas D. Wu,et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing , 2017, Cancer cell.
[45] S. Sidhu,et al. Phage display for selection of novel binding peptides. , 2000, Methods in enzymology.
[46] Jihong Wang,et al. Improving target cell specificity using a novel monovalent bispecific IgG design , 2015, mAbs.
[47] Rutilio H. Clark,et al. A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism* , 2015, The Journal of Biological Chemistry.
[48] I. Tomlinson,et al. Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. , 1994, The EMBO journal.
[49] K. Garcia,et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation , 2016, Proceedings of the National Academy of Sciences.
[50] Lawren C. Wu,et al. Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling* , 2010, The Journal of Biological Chemistry.
[51] M. Graf,et al. Multiparameter RNA and Codon Optimization: A Standardized Tool to Assess and Enhance Autologous Mammalian Gene Expression , 2011, PloS one.
[52] S. Bergqvist,et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity , 2012, Cancer Immunology, Immunotherapy.
[53] T. Clackson,et al. Making antibody fragments using phage display libraries , 1991, Nature.
[54] Jan Berka,et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire , 2009, Proceedings of the National Academy of Sciences.
[55] P. Parren,et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1 , 2014, Nature Protocols.
[56] P. Carter,et al. Alternative molecular formats and therapeutic applications for bispecific antibodies. , 2015, Molecular immunology.
[57] Thomas Waldmann,et al. A novel solid phase technology for high-throughput gene synthesis. , 2008, BioTechniques.
[58] E. Schmidt,et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors , 2017, Clinical Cancer Research.
[59] D R Burton,et al. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[60] Andrew D. Tustian,et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys , 2015, Scientific Reports.
[61] Jan Kubicek,et al. Gene optimization mechanisms: A multi-gene study reveals a high success rate of full-length human proteins expressed in Escherichia coli , 2010, Protein science : a publication of the Protein Society.
[62] I. Melero,et al. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy , 2017, Clinical Cancer Research.
[63] Pavel Strop,et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. , 2012, Journal of molecular biology.
[64] J Witz,et al. Thermodynamic analysis of antigen-antibody binding using biosensor measurements at different temperatures. , 1997, Analytical biochemistry.